ESSA Pharma (NASDAQ:EPIX), a biotechnology company focused on developing treatments for metastatic castration-resistant prostate cancer, saw its stock downgraded by major brokerages Oppenheimer and ...

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on MoonLake Immunotherapeutics (MLTX – Research Report), with ...

(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...

The Atomic Rocketeer, a new feature documentary directed by Larry L. Sheffield and Trent J DiGiulio, tells the story of […] ...

Oppenheimer raised the firm’s price target on Astria Therapeutics (ATXS) to $28 from $26 and keeps an Outperform rating on the shares.

Oppenheimer is being re-released on home video with an Ultimate Edition boxset. The expansive set will be arriving on November 18, with pre-orders available now from Amazon for £45. The film may also ...

Oppenheimer responded to the news by downgrading ... a widely used therapy in this field. However, the trial results showed little distinction between the efficacy of the masofaniten-enzalutamide ...